L
Larimar Therapeutics D
D
LRMR
2.59000
USD
-0.16
(-5.65%)
مغلق
حجم التداول
99,353
الربح لكل سهم
-2
العائد الربحي
-
P/E
-2
حجم السوق
165,832,240
العنوان: Larimar Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.